Fourteen weeks. That’s how many weeks all new Novartis parents will get as minimum paid parental leave, regardless of gender, rolling out from July 1, 2019.

Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.

Novartis and other industry leaders call for action to address antimicrobial resistance, one of the world’s most serious public health challenges

RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.

Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.

Through a successful patient support program, Novartis is taking diabetes care beyond the pill in India.

Results of the Sickle Cell World Assessment Survey (SWAY) highlight the impact this debilitating disease has on patients and their families.